The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1167
October 13, 2003
View Complete Issue         Table of Contents 2019 
Rosuvastatin - a New Lipid-lowering Drug
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rosuvastatin - a New Lipid-lowering Drug
October 13, 2003 (Issue: 1167)
Rosuvastatin (Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol levels. Rosuvastatin, like other statins,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rosuvastatin - a New Lipid-lowering Drug
Article code: 1167a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.